{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:14:50Z","timestamp":1790644490888,"version":"4.1.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1097\/bor.0b013e3283295fec","type":"journal-article","created":{"date-parts":[[2010,2,25]],"date-time":"2010-02-25T06:51:55Z","timestamp":1267080715000},"page":"224-230","source":"Crossref","is-referenced-by-count":92,"title":["Clinical value of blocking IL-6 receptor"],"prefix":"10.1097","volume":"21","author":[{"given":"Toru","family":"Mima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiro","family":"Nishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210128","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60784-3","article-title":"New therapies for treatment of rheumatoid arthritis","volume":"370","author":"Smolen","year":"2007","journal-title":"Lancet"},{"key":"R2-6-20210128","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/ncprheum0338","article-title":"Interleukin-6: from bench to bedside","volume":"2","author":"Nishimoto","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"key":"R3-6-20210128","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/ni1254","article-title":"Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages","volume":"6","author":"Harrington","year":"2005","journal-title":"Nat Immunol"},{"key":"R4-6-20210128","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1084\/jem.20041257","article-title":"IL-23 drives a pathogenic T cell population that induces autoimmune inflammation","volume":"201","author":"Langrish","year":"2005","journal-title":"J Exp Med"},{"key":"R5-6-20210128","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/ni1261","article-title":"A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17","volume":"6","author":"Park","year":"2005","journal-title":"Nat Immunol"},{"key":"R6-6-20210128","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1172\/JCI28508","article-title":"The IL-23\/IL-17 axis in inflammation","volume":"116","author":"Iwakura","year":"2006","journal-title":"J Clin Invest"},{"key":"R7-6-20210128","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature04754","article-title":"Transforming growth factor-\u03b2 induces development of the TH17 lineage","volume":"441","author":"Mangan","year":"2006","journal-title":"Nature"},{"key":"R8-6-20210128","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature04753","article-title":"Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells","volume":"441","author":"Bettelli","year":"2006","journal-title":"Nature"},{"key":"R9-6-20210128","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1146\/annurev.immunol.21.120601.141122","article-title":"Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses","volume":"22","author":"Sakaguchi","year":"2004","journal-title":"Annu Rev Immunol"},{"key":"R10-6-20210128","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1084\/jem.20030152","article-title":"Conversion of peripheral CD4+CD25\u2212 naive T cells to CD4+CD25+ regulatory T cells by TGF-\u03b2 induction of transcription factor Foxp3","volume":"198","author":"Chen","year":"2003","journal-title":"J Exp Med"},{"key":"R11-6-20210128","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1172\/JCI200420945","article-title":"IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin","volume":"113","author":"Nemeth","year":"2004","journal-title":"J Clin Invest"},{"key":"R12-6-20210128","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/art.11143","article-title":"Antiinterleukin-6 receptor antibody therapy reduced vascular endothelial growth factor production in rheumatoid arthritis","volume":"48","author":"Nakahara","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R13-6-20210128","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.4049\/jimmunol.152.8.4149","article-title":"Vascular endothelial growth factor A cytokine modulating endothelial function in rheumatoid arthritis","volume":"152","author":"Koch","year":"1994","journal-title":"J Immunol"},{"key":"R14-6-20210128","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nm0195-27","article-title":"Angiogenesis in cancer, vascular, rheumatoid, and other disease","volume":"1","author":"Folkman","year":"1995","journal-title":"Nat Med"},{"issue":"Suppl 3","key":"R15-6-20210128","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1186\/ar575","article-title":"Angiogenesis in rheumatoid arthritis","volume":"4","author":"Paleolog","year":"2002","journal-title":"Arthritis Res"},{"key":"R16-6-20210128","doi-asserted-by":"crossref","first-page":"11924","DOI":"10.1073\/pnas.90.24.11924","article-title":"Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6","volume":"90","author":"Tamura","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R17-6-20210128","first-page":"851","article-title":"Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth","volume":"53","author":"Sato","year":"1993","journal-title":"Cancer Res"},{"key":"R18-6-20210128","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1146\/annurev.immunol.15.1.797","article-title":"gp130 and the interleukin-6 family of cytokines","volume":"15","author":"Taga","year":"1997","journal-title":"Annu Rev Immunol"},{"key":"R19-6-20210128","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1358\/dot.2006.42.9.1025692","article-title":"Tocilizumab: blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders","volume":"42","author":"Paul-Pletzer","year":"2006","journal-title":"Drugs Today (Barc)"},{"key":"R20-6-20210128","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","article-title":"Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease","volume":"112","author":"Nishimoto","year":"2008","journal-title":"Blood"},{"key":"R21-6-20210128","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1002\/art.20303","article-title":"Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody. A multicenter, double-blind, placebo-controlled trial","volume":"50","author":"Nishimoto","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R22-6-20210128","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1002\/art.22033","article-title":"Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate","volume":"54","author":"Maini","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R24-6-20210128","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1136\/ard.2006.068064","article-title":"Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x-ray reader-blinded randomized controlled trial of tocilizumab","volume":"66","author":"Nishimoto","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R25-6-20210128","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","article-title":"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial","volume":"371","author":"Smolen","year":"2008","journal-title":"Lancet"},{"key":"R26-6-20210128","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1002\/art.23940","article-title":"Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study","volume":"58","author":"Genovese","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R27-6-20210128","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/art.22331","article-title":"Outcomes after switching from one antitumor necrosis factor alpha agent to a second antitumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study","volume":"56","author":"Hyrich","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R28-6-20210128","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1136\/ard.2003.009589","article-title":"Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense","volume":"62","author":"van Vollenhoven","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"R29-6-20210128","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1186\/ar1881","article-title":"Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period","volume":"8","author":"Gomez-Reino","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"R30-6-20210128","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","article-title":"Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition","volume":"353","author":"Genovese","year":"2005","journal-title":"N Engl J Med"},{"key":"R31-6-20210128","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to antitumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R32-6-20210128","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/ard.2008.092932","article-title":"IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to antitumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial","volume":"67","author":"Emery","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"Suppl","key":"R34-6-20210128","first-page":"L59","article-title":"Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with an inadequate response to methotrexate [abstract]","volume":"58","author":"Kremer","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"Suppl II","key":"R37-6-20210128","first-page":"335","article-title":"Safety profile of tocilizumab in Japanese patients with rheumatoid arthritis: incidences of infections in Japanese long-term clinical studies.","volume":"67","author":"Nishimoto","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 2","key":"R38-6-20210128","first-page":"122","article-title":"Incidence of malignancies in Japanese rheumatoid arthritis patients treated with tocilizumab in comparison to those in an observational cohort of Japanese patients and a Japanese population database.","volume":"66","author":"Yamanaka","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R39-6-20210128","doi-asserted-by":"crossref","first-page":"H2954","DOI":"10.1152\/ajpheart.2000.279.6.H2954","article-title":"Interleukin-6 induces demargination of intravascular neutrophils and shortens their transit in marrow","volume":"279","author":"Suwa","year":"2000","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"R40-6-20210128","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/00002281-200309000-00010","article-title":"Interleukin 6 as a therapeutic target in systemic-onset juvenile idiopathic arthritis","volume":"15","author":"Yokota","year":"2003","journal-title":"Curr Opin Rheumatol"},{"key":"R41-6-20210128","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","article-title":"Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial","volume":"371","author":"Yokota","year":"2008","journal-title":"Lancet"},{"key":"R42-6-20210128","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1002\/art.10620","article-title":"Humanized monoclonal antiinterleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease","volume":"46","author":"Iwamoto","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R44-6-20210128","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1002\/art.23373","article-title":"Successful treatment of a patient with Takayasu arteritis using a humanized antiinterleukin-6 receptor antibody","volume":"58","author":"Nishimoto","year":"2008","journal-title":"Arthritis Rheum"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0b013e3283295fec","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T21:49:51Z","timestamp":1739915391000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-200905000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0b013e3283295fec","relation":{},"ISSN":["1040-8711"],"issn-type":[{"value":"1040-8711","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5]]}}}